Kornimate/medical-research-clean huggingface dataset:
two doses of the intravenous magnesium sulfate versus the standard single dose ,with/ without the nebulized budesonide for the management of the severe asthma exacerbation in the emergency room; a randomized controlled trial.

Conditions: Bronchial Asthma

Summary: many studies have investigated the efficacy and safety of intravenous magnesium sulfate and inhaled steroids in addition to the standard treatment for patients with severe asthma attacks. in this 2x2 factorial design blinded randomized study, no interaction of hypothesized treatments is expected.investigators hypothesize that two doses of intravenous magnesium sulfate,a high dose followed by a (lower) standard dose, will shorten the time to medical readiness for discharge compared to a single standard dose followed by placebo.the second hypothesis is that nebulized inhaled budesonide will be superior to placebo.

patient with a severe asthma attack will be admitted to the observation area in the pediatric emergency center and assessed for eligibility for the study by the attending physician, based upon our study inclusion/exclusion criteria. eligible patients will be enrolled after obtaining written consent from the parents. patients will receive routine treatment for a severe asthma attack, such as inhaled bronchodilators, plus intravenous steroids and supplementary oxygen if needed. standard blood work and chest x-ray will be obtained and bronchial asthma severity score will be measured at baseline before starting treatment,and then at 4,8,12,24,36,48 hr and thereafter. the medical team as well as parents and patient will be blinded to the medications delivered. the patient will be randomized into one of the four study groups and adverse effects of the medications in each group will be monitored and documented carefully.

Eligibility criteria:
inclusion criteria: 1. children 2-14 years of age. 2. known to have bronchial asthma. 3. presenting in severe asthma exacerbation 4. asthma severity score 8 or higher according to pram asthma severity . exclusion criteria: 1. prematurity \<34 weeks of gestation. 2. critically ill children requiring immediate intubation or icu admission. 3. transfers from other institutions. 4. adverse drug reaction or allergy to budesonide,salbutamol,ipratropium bromide, prednisone, prednisolone, methylprednisolone, or magnesium sulfate. 5. history of neuromuscular disease, cardiac disease, renal disease, liver disease. 6. underlying chronic lung disease. 7. radiographic evidence of pneumonia or lung collapse . 8. hemodynamic instability. 9. instrumented airway or tracheotomy. 10. colostomy or ileostomy. 11. malabsorption disorder. 12. known vitamin d deficiency. 13. receiving milk of magnesium for constipation 14. chronic diarrhea (duration for 2 weeks) 15. diuretics use. 16. immunodeficiency.

Keywords: bronchial asthma intravenous magnesium sulfate inhaled budesonide
neutrophil lymphocyte ratio as a predictor of outcome in critically traumatic patients

Conditions: Critical Care

Summary: neutrophil lymphocyte ratio nlr is an important index that evaluate the inflammatory status . it is a cost effective and readily available , and simply calculated , so that why investigators try to use it as a predictor of short term survival in the critically ill patients

nlr will be used as predictor for short term survival and patients stay in icu in 2 groups of patients . investigators will use it in a group of medical critically ill patients as respiratory failure , neuromuscular disorders , renal impairment . the other group is the critically ill surgical patients , as patients with multiple trauma , post major surgery

Eligibility criteria:
inclusion criteria: * critically ill trauma patients exclusion criteria: * auto immune disease endocrine disease renal dysfunction hepatic dysfunction malignancy smoking

Keywords: critical care neutrophils lymphocytes
a study of the comparative effectiveness of deucravacitinib in adults with plaque psoriasis in japan (rephlect)

Conditions: Plaque Psoriasis

Summary: this is a prospective, observational, real-world study of adult participants in japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.


Eligibility criteria:
inclusion criteria: * japanese adult participants aged 18 years old or older * physician-reported diagnosis of plaque psoriasis * newly initiating deucravacitinib or apremilast according to the label * participants who have signed informed consent exclusion criteria: * participants currently participating in or planning to participate in an interventional clinical trial * patients enrolled in deucravacitinib post-marketing surveillance study (clinicaltrial.gov id: nct05633264) * previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib)
association between tumor size and prognosis in patients with small bowel adenocarcinoma-a seer-based study

Conditions: Prognosis

Summary: the goal of this observational study is to learn about in small bowel adenocarcinoma patients. the main question it aims to answer is the association between tumor size and prognosis in patients with small bowel adenocarcinoma. participants will be compared for the relationship between tumor size and prognosis.


Eligibility criteria:
inclusion criteria: 1. pathology confirmed as sba; 2. received surgery and complete postoperative follow-up data; 3. histology type code 8140-8380. exclusion criteria: cases with unknown tumor location, size, tnm staging, race, and degree of differentiation were excluded. finally, 8,163 eligible patients were included in the analysis
clinical efficacy of a toothpaste in providing relief from the pain of dentinal hypersensitivity

Conditions: Dentine Hypersensitivity

Summary: a study to compare the efficacy of a test dentifrice against a control dentifrice in reducing dentinal hypersensitivity over a two week treatment period.


Eligibility criteria:
- subjects who suffer from tooth sensitivity.
dotarem vs gadobutrol contrast for breast mri

Conditions: Breast Diseases

Summary: in this randomized clinical trial, the investigators expect to demonstrate that the mri contrast agent dotarem is not less effective in contrast enhancement of breast lesions then gadavist. participants will be randomized to receive either dotarem or gadavist. in all cases, inclusion criteria will require patients having undergone or scheduled or most likely to be scheduled to undergo tissue sampling with histology results available. the patients will be prospectively and consecutively identified such that the majority of patients included will have been diagnosed with breast cancer, while including benign disease in the minority of patients in each arm. following randomized enrollment, quantitative, semi-quantitative and qualitative image analysis will be performed to objectively assess for differences in image quality and diagnostic value.

a stratified randomization of participants based on the time of menstural cycle and breast density. women will then receive their clinically indicated breast mri with contrast, using soc procedures for weight-based dosage. after enrollment, mri images and medical metadata will be abstracted using the hospital medical records in epic and pacs databases. data to be collected from the medical record includes histology parameters: tumor, tumor type and size, grade, stage and personal data: mrn, accession number, date of birth, date of mri, age, sex, race/ethnicity, family history. images will be stripped of identifiers and then coded by a study id using the third party santesoft dicom editor software. medidata will also be coded and stored separately from a mastercode file linking the study id with the following identifiable information: mrn, accession number, date of birth, and date of mri. after a period of data collection, two radiologists blinded to the contrast agent will independently review the the mris. this qualitative review will consist of each exam being graded on a scale of 1-(fail) to 5-(excellent) contrast enhancement quality. additionally, each blinded radiologist or designee will conduct the secondary quantitative measurements of the wash-in/wash-out contrast characteristics through use of computer aid design (cad) in pacs.

Eligibility criteria:
inclusion criteria: * females age 18 and older * scheduled to undergo a clinically indicated mri of the breast with contrast. * have undergone, are scheduled to undergo, or are likely to be scheduled to undergo a breast tissue sampling exam with histology results available within 6 months of their mri. exclusion criteria: * pregnant * have already begun therapeutic treatment for breast cancer including surgery (lumpectomy or mastectomy), radiotherapy, or chemotherapy. * pre menopause women outside of the 7-14 days from cycle

Keywords: breast mri mammography dotarem contrast gadobutrol contrast wash-in/wash-out contrast curve contrast enhanced mri
targeted intervention for patient centered outcome in patients with idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: idiopathic pulmonary fibrosis (ipf), a chronic fibrotic lung disease of unknown cause, is characterized by relentless progression, with a three-year mortality of up to 50%. ipf has high morbidity, with 90% of patients reporting dyspnea at the time of diagnosis and this is strongly correlated with quality of life and mortality. as ipf progress, breathlessness worsens, physical functional capacity declines, and health-related quality of life deteriorates. pulmonary rehabilitation (pr) can improve well-being in patients with other chronic lung disease, but little is known regarding pr in ipf.

the hypothesis is that the provision of a comprehensive pulmonary rehabilitation program to patients with ipf will significantly improve participant health related quality of life. the objective is to develop a comprehensive, multi-disciplinary 12-week pr program with disease specific educational components for ipf patients. the specific aims of the proposal is to evaluate the effect of the comprehensive pr program on 1) improvements in quality of life using the medical outcomes study 36-item short form 36 (sf-36), a quality of life instrument and 2) improvements in patient self-reported dyspnea scores using the chronic respiratory questionnaire. the investigator intends to evaluate sustained benefits of the pr intervention, changes in depression, anxiety, stress and functional physical capacity.

Eligibility criteria:
inclusion criteria: * diagnosis of ipf confirmed by lung biopsy or by characteristic pattern on high resolution computed tomogram (hrct) * no identifiable cause of lung fibrosis * pr not received in the past year * ability to walk exclusion criteria: * history of unstable angina * deterioration cardiac or neurological disease * pregnancy or lactation * degenerative arthritis or other limitation to mobility * pr in the past 12 months
cgm and lifestyle changes in patients with impaired glucose tolerance

Conditions: Impaired Glucose Tolerance

Summary: the incidence of type 2 diabetes (t2d) in children is increasing, paralleling the rising incidence of obesity. preventing children and adolescents from developing t2d is critical. the health benefits of lifestyle modifications are well documented in this population, but success rates are low. obesity in children and adolescents increases the risk of not only t2d but other complications as well, such as hypertension, dyslipidemias and more. the investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (cgm) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. as a result, a decrease in body mass index (bmi) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood/adolescence and adulthood.

the purpose of this research is to evaluate if having blood sugar information from a continuous glucose monitor (cgm) during activities of daily living provides additional benefit to lifestyle modifications in reducing the risk of developing diabetes and achieving a healthier weight. a cgm is a small device often worn on the back of the arm that uses a very small needle to insert a small sensor just under the skin in the fatty tissue. the cgm device transmits the blood sugar level to either a smartphone or a special receiver. the investigators expect patients will have an overall improvement in health by decreasing weight and therefore improving the way the child's insulin works in their body. this could result in decreased risk of obesity-related complications such as diabetes mellitus, cardiovascular disease, kidney disease, and loss of vision and/or limbs, among others.

Eligibility criteria:
inclusion criteria: 1. children 10 to \<17 years old (i.e., before their 17th birthday) 2. impaired glucose tolerance based on standardized oral glucose tolerance test (ogtt) or fasting glucose per american diabetes association criteria, 3. overweight or obese (bmi ≥85th percentile for age/sex) 4. patients are pubertal, defined as females with breast tanner stage ii or above, or males with testicular volume ≥4 ml exclusion criteria: 1. existing diagnosis of type 1 or type 2 diabetes 2. prepubertal 3. taking medications that affect insulin sensitivity (e.g.,chronic corticosteroids whether systemic or inhaled). metformin allowed if stable dose. 4. patients and/or families not willing to wear the cgm for the duration of the study period or lack of compliance after recruitment

Keywords: impaired glucose tolerance obesity adolescents
evaluation of the effectiveness of arthrocentesis using catheter in the treatment of temporamandibular joint disorders

Conditions: TMJ Disc Disorder; Treatment; Arthrocentesis

Summary: the study focused on arthrocentesis performed using a catheter, aiming to assess its effects on pain perception and mouth opening in patients with tmj disorders.

two groups will be formed consisting of patients who present with complaints of tmj pain, limited mouth opening and hearing sounds in the joint and are diagnosed with tmj disorder. after explaining the i-prf protocol obtained by taking blood to both groups and obtaining the necessary consents, arthrocentesis will be performed on the relevant joint area using a catheter for the patients in the first group and a single needle for the patients in the second group. patients will be called for check-ups on the 1st day, 1st week and 1st month after the protocols and the current perceived pain level before and after the treatment will be determined by scoring with visual analog scala (vas) and measuring the mouth opening with a ruler ( mm).

Eligibility criteria:
patients included in this study were adult individuals aged 18 years and older who were diagnosed with stage 3 or higher temporomandibular joint (tmj) disorder according to the wilkes classification, based on magnetic resonance imaging (mri) in addition to clinical evaluation. eligible patients had unilateral internal tmj disorder and exhibited clinical symptoms such as tmj-related pain and/or joint sounds, and limited mouth opening. furthermore, only patients whose symptoms persisted despite at least one month of occlusal splint therapy were included. exclusion criteria were as follows: patients diagnosed with myofascial pain or muscle-related functional limitation; those who had previously undergone intra-articular injection or other invasive procedures involving the tmj; patients with connective tissue diseases such as rheumatoid arthritis or with neurological disorders; patients with a history of major jaw trauma; and individuals with psychiatric disorders or a history of substance abuse.

Keywords: branul
lidocaine 10% spray reduces pain during intrauterine device insertion

Conditions: Pain

Summary: pain during intrauterine device (iud) insertion can be a barrier to initiation. misoprostol and nonsteroidal drugs have found to be ineffective by clinical trials.investigators tested whether intracervical 2% lidocaine gel decreased insertion pain compared to placebo.


Eligibility criteria:
inclusion criteria: age \>18 not pregnant smear negative exclusion criteria: chronic pelvic pain pregnancy uterine anomaly fibroid acute cervicitis pelvic inflammatory disease cervical stenosis

Keywords: scores during iud insertion.
mobile lung cancer screening

Conditions: Lung Cancer Prevention

Summary: lung cancer screening using low-dose ct (ldct) has been shown to reduce mortality in high-risk populations. in 2022, the french national cancer institute (inca) issued guidelines recommending screening for individuals aged 50-74 with a history of heavy smoking, including current smokers or those who quit less than 15 years ago. a national pilot program (impulsion) will be launched in 2025. lung cancer incidence is strongly correlated with socioeconomic status, yet underserved populations remain difficult to engage in screening programs. mobile health units using a "reach-out" strategy have demonstrated effectiveness in other countries (uk, brazil, usa). in france, this approach has been used for breast cancer screening via mobile mammography units. the mobilyad project aims to compare two screening modalities- a mobile demedicalized unit (ct-equipped van with trained nurses) and a conventional hospital-based unit- to assess the effectiveness of mobile screening in reaching socially disadvantaged populations.


Eligibility criteria:
inclusion criteria \* : * persons aged over 50 and under 75 (74 years of age or older). * active smokers or former smokers who quit less than 15 years ago. * persons whose consumption is estimated at 20 packs/year or more, down to ≥15 cigarettes/day for a duration of consumption of ≥25 years and up to ≥10 cigarettes/day for ≥30 years, which takes into account the predominance of duration of consumption over quantity consumed in the risk of lung cancer. a pack-year corresponds to the consumption of one pack of 20 manufactured cigarettes per day for one year. a multiplier coefficient will be taken into account depending on the mode of consumption: rolled cigarettes: 2; cigarillos: 3; cigars: 4; pipes: 2.5; hookahs: 25. * persons affiliated with social security. - person having signed their consent to participate in the study after having received full information about it, including the risks associated with participation. * exclusion criteria \* : * individuals with severe comorbidities contraindicating lung cancer investigations and/or treatment (including surgery or stereotactic radiotherapy); * individuals with impaired general condition (ps 2 and above); * individuals with dyspnea at rest (mmrc4); * individuals with a history of cancer undergoing active surveillance by chest computed tomography (ct or pet scan); personal history of lung cancer (lifetime); * individuals with symptoms suggestive of lung cancer (hemoptysis, unexplained weight loss, recent onset or change in respiratory symptoms, etc.); * individuals refusing to participate in the study * individuals withdrawing their consent.

Keywords: prevention lung cancer screening tobacco
effects of atx and oros-mph on executive functions

Conditions: Executive Dysfunction

Summary: the aim of this study was to evaluate and compare the effects of atomoxetine(atx) and osmotic release oral system-methylphenidate (oros-mph) therapies on executive functions, activities, treatment response time and adverse effects based on discernible clinical effects in children with combined type attention deficit-hyperactivity disorder (adhd).

the aim of this study was to evaluate and compare the effects of atomoxetine(atx) and osmotic release oral system-methylphenidate (oros-mph) therapies on executive functions, activities, treatment response time and adverse effects based on discernible clinical effects in children with combined type attention deficit-hyperactivity disorder (adhd). in this study, the functional capabilities of the patients who clinically responded well to therapy were assessed simultaneously with clinical response that may appear at different time periods and the treatment groups were compared in patients who responded to therapy by excluding patients with insufficient clinical response.

Eligibility criteria:
inclusion criteria: * combined type adhd diagnosis was made by a child psychiatrist according to dsm-iv criteria through k-sads interview with the patient and mother * the clinical global impression scale (cgi-s) was applied to determine adhd severity and patients with a cgi-s score≥4 exclusion criteria: * psychological, neurological or psychiatric diseases other than adhd, * adhd types other than combined type, * medication that influences cognitive processes or history of such medication, * wisc-r scores \ 120

Keywords: attention deficit-hyperactivity disorder (adhd). executive functions
ultrasonographic insulin versus dexamethasone injection with local anestheticss in diabetic patients with mild to moderate median nerve entrapement neuropathy .

Conditions: Pain, Neuropathic

Summary: insulin injection in carpal tunnel compared with dexamethsone in diabetic patients

trial to decrease median nerve entrapement neuropathy recurrence using insulin co-injection

Eligibility criteria:
inclusion criteria: * all diabetic patients with carpal tunnel syndrome exclusion criteria: * refusal to participate
a study of abbv-428, an immunotherapy, in subjects with advanced solid tumors

Conditions: Advanced Solid Tumors Cancer

Summary: this is an open-label, phase i, dose-escalation study to determine the recommended phase 2 dose (rptd), maximum tolerated dose (mtd), and evaluate the safety and pharmacokinetic (pk) profile of abbv-428 when administered as monotherapy or in combination with nivolumab in participants with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * participants must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies. * participants have adequate bone marrow, renal, hepatic and coagulation function. * for all dose expansion arms, participants must have measurable disease per response evaluation criteria in solid tumors (recist) version 1.1 * participants in combination therapy cohorts must have an advanced solid tumor where the use of nivolumab is standard therapy. exclusion criteria: * active or prior documented autoimmune disease in the last 2 years. participants with childhood atopy or asthma, vitiligo, alopecia, hashimoto syndrome, grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. * current or prior use of immunosuppressive medication within 14 days prior to the first dose (with certain exceptions). * history of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis. * confirmed positive test results for human immunodeficiency virus (hiv), or participants with chronic or active hepatitis b or c. participants who have a history of hepatitis b or c who have undetectable hbv dna or hcv rna after anti-viral therapy may be enrolled. * prior grade greater than or equal to 3 immune-mediated neurotoxicity or pneumonitis (or any other unresolved or symptomatic adverse event in the last 3 months) while receiving immunotherapy. * male participants who are considering fathering a child or donating sperm during the study or for at least 3 or 5 months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.

Keywords: cancer neoplasm advanced solid tumor nivolumab non-small cell lung cancer (nsclc) non-squamous nsclc ovarian cancer